Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

Sigma-Aldrich Purchases NextGen’s Electrophoresis Franchise

  • NextGen Sciences divested its electrophoresis business to Sigma-Aldrich for an up-front fee and royalties for three years. This completes NextGen’s realignment to a biomarker services business.

    Under the deal with Sigma-Aldrich, NextGen has sold its automated gel casting unit called a2DEoptimizer™ and the range of large format precast gels known as optigels™. Sigma-Aldrich will focus primarily on the supply of optigels, initially to the North American and European markets.

    In December 2008, NextGen sold its gene-to-protein automation and software business to eXeTek, a spinout led by two former NextGen employees. NextGen also acquired a 24% stake in eXeTek at the time and will receive 5% royalties for three years.

    Launched in November 2007, NextGen Sciences’ service portfolio called biomarkerexpress™ includes biomarker discovery, assay development, and testing.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »